Free PDF Download

Total Page:16

File Type:pdf, Size:1020Kb

Free PDF Download European Review for Medical and Pharmacological Sciences 2013; 17: 410-419 Pattern analysis and variations in the utilization of antihypertensive drugs in Taiwan: a six-year study L.-Y. HUANG1,2, W.-Y. SHAU1, H.-C. CHEN3, S. SU2, M.-C. YANG2, H.-L. YEH4,5, M.-S. LAI3,6 1Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan 2Graduate Institute of Health Care Organization Administration, College of Public Health, National Taiwan University, Taipei, Taiwan 3Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan 4Department of Cardiology, Sijhih Cathay General Hospital, Taipei, Taiwan 5School of Public Health, College of Public Health and Nutrition, Taipei Medical University, Taipei, Taiwan 6Center for Comparative Effectiveness Research, National Clinical Trial and Research Center, National Taiwan University Hospital, Taipei, Taiwan Abstract. – BACKGROUND: In the last few CONCLUSIONS: The consumption of antihy- years there have been changed in the pattern of pertension drugs in Taiwan increased during the consumption of antihypertensive drugs in other period studied and the highest average annual countries. Factors causing this variability in- increases were for ARBs and CCBs. Overall con- clude differences in the effectiveness of detec- sumption of antihypertension drugs also in- tion, guidelines for the management of hyperten- creased in other countries, but differences in the sion, and differences in national health insur- relative increase for each class of drug suggest ance systems among countries. that further study may be required to clarify the AIM: The aim of this study was to reveal pat- origins and causes. terns in the use of antihypertensive drugs in Tai- wan over a six year period (2001 to 2006) and com- Key Words: pare these results with data from other countries. Antihypertensive drugs, Total defined daily dose, MATERIALS AND METHODS: This study per- Angiotensin-II receptor blockers, Calcium channel formed descriptive analysis of data from the Nation- blockers, Angiotensin-converting enzyme inhibitors. al Health Insurance Research Database (NHIRD) of Taiwan, and compared these findings with similar findings from around the world. Quantities were standardized using the defined daily dose (DDD) per 1000 inhabitants per day (DID) in accordance with WHO anatomical therapeutic classification and Introduction DDD measurement methodology. RESULTS: The total number of DDDs pre- Considerable variability in the prevalence of scribed in Taiwan increased from 0.66 billion in hypertension (5.3 to 42.3% of different popula- 2001 to 1.08 billion in 2006, representing 80.6 tions) has been observed in previous studies1. and 129.2 DID in 2001 and 2006, respectively. This variability may be due to differences in the This indicates a significant increase in the pre- 2,3 scription of antihypertensive drugs in Taiwan measurement of blood pressure , age ranges, over this period. The average annual increase and the definitions used for hypertension4. In the ranged from 10.7% for calcium channel blockers last few years there have been changed in the (CCBs) to 22.1% for angiotensin II receptor pattern of consumption of antihypertensive blockers (ARBs). All of these patterns were sta- drugs in other countries1. The factors causing tistically significant (p < 0.05). The rapid increase this variability include differences in the effec- in the use of ARBs resulted in its surpassing 1 ACEIs with the second highest DID (21.9) in tiveness of detection , different guidelines for 1 2006. Though the proportional use of CCBs and the management of hypertension , differences in ARBs has increased significantly, the use of thi- the national health insurance systems of various azide diuretics remains low. countries1, differences in the measurement of 410 Corresponding Author: Mei-Shu Lai, MD; e-mail: [email protected] Pattern analysis and variations in the utilization of antihypertensive drugs in Taiwan: a six-year study blood pressure2,3, different definitions of hyper- 3. Beta blocking agents (BBs): C07A A. Non-se- tension4 and different age ranges1. Few studies lective beta blocking agents, plain; C07A B. have specifically investigated patterns in the use Selective beta blocking agents, plain; C07A G. of antihypertensive drugs in Taiwan. Chou et al. Alpha and beta blocking agents; C07B, C07C presented the patterns of antihypertensive med- and C07D. Beta blocking agents and diuretics; ications in Taiwan according to their pharmaco- C07F. Beta blocking agents and other antihy- logical classifications5. Their results indicated pertensives8,9; that calcium antagonists were the most frequent- 4. Calcium channel blockers: C08: C08C and ly prescribed antihypertensive medication, ap- C08D. Calcium channel blockers8,9; pearing in 54.9% of all hypertension related pre- 5. ACE inhibitors (ACEIs): C09A. ACE in- scriptions in 19985. The second was beta-block- hibitors, plain; C09B A. ACE inhibitors and ers (43.5%), followed by angiotensin-converting diuretics; C09B B. ACE inhibitors and calcium enzyme inhibitors (ACEIs) (31.5%), and diuret- channel blockers8,9; ics (23.2%)5. The aim of this study was to de- 6. Angiotensin II antagonists (ARBs): C09C. An- scribe the utilization patterns of antihypertensive giotensin II antagonists, plain; C09D. An- drugs in Taiwan over a six-year period (2001- giotensin II antagonists, combinations8,9. 2006) and compare the results with data from 7. Other antihypertensives: C02CA. Alpha- other countries. adrenoreceptor antagonists; C02A. Antiadrener- gic agents, centrally acting; C02D. Arteriolar smooth muscle, agents acting on; C02L. Antihy- Materials and Methods pertensives and diuretics in combination8,9. Data Collection Method of Analysis This study employed descriptive analysis of all Medications were quantified in defined daily prescriptions for antihypertensive drugs between doses by assigning defined daily dose (DDD) 2001 and 2006, from the National Health Insur- units to each NHIRD item using the Anatomical ance Research Database (NHIRD) of Taiwan. Therapeutic Chemical (ATC) classification sys- The NHI is the Taiwanese universal health insur- tem8. All NHIRD items are classified by the ATC ance program implemented in March 1995. By classification system, and can be directly linked 2006, the NHI covered approximately 98% of the to DDD units using the ATC Index9. Taiwanese population, and 97% of hospitals and First, the total number of DDDs dispensed in clinics throughout the nation6,7. Antihypertensive each record of the NHIRD set is calculated to de- drugs were evaluated according to the Anatomi- termine the dose strength for each item using the cal Therapeutical Chemical Classification/De- following formula9,10: fined Daily Doses (ATC/DDD) system developed N*M*Q by the World Health Organization8,9. This study DDDs = ––––––––––– categorized the antihypertensive drugs into seven DDD unit major classes (ATC codes are listed in parenthe- ses): renin-angiotensin system (ACEIs, C09A, where N is the number of prescriptions dis- C09B), angiotensin-II receptor blockers (ARBs, pensed per record, M is the strength of each dose C09C, C09D); beta-blockers (C07); calcium (milligrams), Q is the average quantity of doses channel blockers (CCB) (C08); thiazide-type di- per prescription and DDD unit is one defined uretics (C03A); other diuretics (C03B, C03C, daily dose for the particular NHIRD item9. When C03D, C03E); and others (C02)8,9. All anti-hy- used for comparison, the number of DDDs pre- pertensive drugs considered in this study be- scribed is generally given per 1000 inhabitants longed to subgroups of the seven major therapeu- per day9,10. This method of standardization ad- tic groups, classified as follows8,9: justs for the size of the population under study, enabling meaningful comparisons of drug use 1. Thiazide type Diuretics: C03A across years and among different countries9,12. 2. Other Diuretics: C03B. Low-ceiling diuretics, Population related data was obtained from Na- plain; C03C. High-ceiling diuretics, plain; tional Statistics in Taiwan11. This study presents C03D. Potassium-sparing agents, plain; C03E. the DDDs per 1000 inhabitants per day (DID)9,12 Diuretics and potassium-sparing agents in com- of each ATC category by the year and throughout bination. the entire period of study. 411 L.-Y. Huang, W.-Y. Shau, H.-C. Chen, S. Su, M.-C. Yang, H.-L. Yeh, M.-S. Lai Data Sources software SAS for Windows (version 9.1; SAS In- The data in this study was derived from the en- stitute, Cary, NC, USA) was used to conduct all tire population of Taiwan, because everyone is data analysis. insured according to the law. Since March 1, 1995, when Taiwan implemented universal na- tional health insurance (NHI) legislation, cover- Results age has increased from 57% to 98% of the popu- lation6,13. As of 2007, 22.60 million of Taiwan’s For the drugs included in the present study, the 22.96 million citizens were enrolled in this pro- total number of DDDs prescribed in Taiwan in- gram8. This data (which includes outpatient and creased from 0.66 billion in 2001 to 1.08 billion in inpatient records) provides national estimates of 2006, representing 80.1 and 129.2 DID in 2001 exposure to antihypertensive drugs, enables the and 2006, respectively. This indicates a significant monitoring of changes in usage and allows com- increase in the prescription of antihypertensive parison of data from Taiwan with those from oth- drugs in Taiwan over this period. Figure 1 presents er countries. the DID and annual trends according to ATC groupings of antihypertensive drugs used from Statistical Analysis 2001 to 2006. All seven classes of drugs showed To analyse annual trends in the use of these an increase in use with average yearly increases drugs, this study employed linear regression to from 4.5% for ACE inhibitors to 22.1% for ARB calculate the mean change of DID per year, using (Figure 1). All of the trends are statistically signifi- DID as a dependent variable and regressed yearly cant (p < 0.05) (Figure 1). Among the classes of figures as continuous variables.
Recommended publications
  • Angiotensin-Converting Enzyme Inhibitors Or Angiotensin II Receptor Blockers and the Risk of Developing Rheumatoid Arthritis in Antihypertensive Drug Users
    Jong, H.J.I. de, Vandebriel, R.J., Saldi, S.R.F., Dijk, L. van, Loveren, H. van, Cohen Tervaert, J.W., Klungel, O.H. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiology and Drug Safety: 2012, 21(8), 835-843 Postprint Version 1.0 Journal website http://dx.doi.org/10.1002/pds.3291 Pubmed link http://www.ncbi.nlm.nih.gov/pubmed/22674737 DOI 10.1002/pds.3291 This is a NIVEL certified Post Print, more info at http://www.nivel.eu Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users†‡ HILDA J. I. DE JONG1,2,3, ROB J. VANDEBRIEL1, SITI R. F. SALDI3, LISET VAN DIJK4, HENK VAN LOVEREN1,2, JAN WILLEM COHEN TERVAERT5, OLAF H. KLUNGEL3,* ABSTRACT Purpose: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are effective in the treatment of cardiovascular disease. Next to effects on hypertension and cardiac function, these drugs have anti-inflammatory and immunomodulating properties which may either facilitate or protect against the development of autoimmunity, potentially resulting in autoimmune diseases. Therefore, we determined in the current study the association between ACE inhibitor and ARB use and incident rheumatoid arthritis (RA). Methods: A matched case–control study was conducted among patients treated with antihypertensive drugs using the Netherlands Information Network of General Practice (LINH) database in 2001–2006. Cases were patients with a first-time diagnosis of RA. Each case was matched to five controls for age, sex, and index date, which was selected 1 year before the first diagnosis of RA.
    [Show full text]
  • Key Features of Candesartan Cilexetil and a Comparison with Other Angiotensin II Receptor Antagonists
    Journal of Human Hypertension (1999) 13, (Suppl 1), S3–S10 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists PS Sever Imperial College of Science, Technology & Medicine at St Mary’s Hospital, London, UK Current research on angiotensin II AT1-receptor antag- in patients with essential hypertension. Candesartan onists (AIIRAs) and selected studies presented at the cilexetil has a rapid onset of action (approximately 80% recent symposium held in Amsterdam, The Netherlands, of total blood pressure reduction within the first 2 on 6 June 1998, titled ‘Angiotensin II Receptor Antagon- weeks) and dose-dependent effects on blood pressure, ists are NOT all the Same’ are reviewed. AIIRAs offer a is comparable in efficacy to a number of classes of anti- number of potential advantages over alternative antihy- hypertensives, and is effective in combination therapy pertensive agents acting via the renin-angiotensin-aldo- (eg, with hydrochlorothiazide and amlodipine). This sterone system. They combine blood pressure-lowering favourable profile may be due in part to the highly selec- effects at least equivalent to those of angiotensin-con- tive, tight binding to and slow dissociation of candesar- verting enzyme (ACE) inhibitors, coupled with placebo- tan from the AT1 receptor. Preliminary studies suggest like tolerability. Candesartan cilexetil is a novel AIIRA that candesartan cilexetil also protects end organs that has demonstrated clinical
    [Show full text]
  • Apo-Cilazapril/Hydrochlorothiazide Film Coated Tablet
    New Zealand Data Sheet APO-CILAZAPRIL/HYDROCHLOROTHIAZIDE 1. PRODUCT NAME APO-CILAZAPRIL/HYDROCHLOROTHIAZIDE – cilazapril 5mg and hydrochlorothiazide 12.5mg film coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Cilazapril monohydrate 5.22mg (equivalent to Cilazapril 5mg) and Hydrochlorothiazide 12.5mg Excipient(s) with known effect HYDROCHLOROTHIAZIDE contains sulphur. APO-CILAZAPRIL/HYDROCHLOROTHIAZIDE is lactose free and gluten free. APO-CILAZAPRIL/HYDROCHLOROTHIAZIDE contains Red Ferric Oxide (orange shade # 34690). For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM APO-CILAZAPRIL/HYDROCHLOROTHIAZIDE are pink, oval biconvex film-coated tablets. Each tablet is engraved “APO” on one side and “5” bisect “12.5” on the other side. Each tablet typically weighs 92mg. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications APO-CILAZAPRIL/HYDROCHLOROTHIAZIDE is indicated for the treatment of patients with hypertension who are not adequately controlled on monotherapy. 4.2 Dose and method of administration Standard Dosage The dosage of APO-CILAZAPRIL/HYDROCHLOROTHIAZIDE is one tablet administered once daily. As food intake has no clinically significant influence on absorption, APO- CILAZAPRIL/HYDROCHLOROTHIAZIDE can be administered before or after meals. The dose should always be taken at about the same time of day. Special Populations Renal insufficiency When concomitant diuretic therapy is required in patients with severe renal impairment, a loop diuretic rather than a thiazide diuretic is preferred for use with cilazapril/hydrochlorothiazide; therefore, for patients with severe renal dysfunction (creatinine Please refer to Medsafe website (www.medsafe.govt.nz) for the most recent datasheet Page 1 of 22 APO-CILAZAPRIL/HYDROCHLOROTHIAZIDE clearance <10ml/min), APO-CILAZAPRIL/HYDROCHLOROTHIAZIDE is not recommended.
    [Show full text]
  • Effective Dose Range of Enalapril in Mild to Moderate Essential Hypertension
    Br. J. clin. Pharmac. (1985), 19, 605-611 Effective dose range of enalapril in mild to moderate essential hypertension R. BERGSTRAND', H. HERLITZ2, SAGA JOHANSSON', G. BERGLUND2, A. VEDIN', C. WILHELMSSON', H. J. GOMEZ3, V. J. CIRILLO3 & J. A. BOLOGNESE4 'Department of Medicine, Ostra Hospital and 2Department of Medicine I, Sahlgrenska Hospital, Goteborg, Sweden and Department of 3Cardiovascular Clinical Research and 4Clinical Biostatistics, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey, USA 1 The dose-response relationship of enalapril was evaluated in a double-blind, balanced, two-period, incomplete-block study in 91 patients with mild to moderate essential hyper- tension. 2 Patients were randomly assigned to two of six treatments: placebo, 2.5, 5, 10, 20 and 40 mg/day of enalapril maleate. There were two 3-week treatment periods, each preceded by a 4-week, single-blind placebo washout. 3 Each dose of enalapril produced significant decreases in standing and supine systolic and diastolic blood pressure after 2 and 3 weeks of treatment. There were no significant changes on placebo. 4 There was a significant linear dose response relationship for both mean blood pressure and mean change from baseline in blood pressure (P < 0.01 for systolic and mean arterial pressure, and P < 0.05 for diastolic pressure). 5 Enalapril was associated with an increasing dose-response relationship across the 2.5- 40 mg/day range. The 2.5 mg/dose is effective in some patients; however, doses ¢ 10 mg/ day may be necessary to achieve satisfactory blood pressure control. Keywords enalapril angiotensin converting enzyme inhibitor dose-response relationship Introduction In recent years much interest has been focused with renal impairment treated with high doses of on angiotensin converting enzyme (ACE) in- captopril.
    [Show full text]
  • A Comparison of the Tolerability of the Direct Renin Inhibitor Aliskiren and Lisinopril in Patients with Severe Hypertension
    Journal of Human Hypertension (2007) 21, 780–787 & 2007 Nature Publishing Group All rights reserved 0950-9240/07 $30.00 www.nature.com/jhh ORIGINAL ARTICLE A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension RH Strasser1, JG Puig2, C Farsang3, M Croket4,JLi5 and H van Ingen4 1Technical University Dresden, Heart Center, University Hospital, Dresden, Germany; 2Department of Internal Medicine, La Paz Hospital, Madrid, Spain; 31st Department of Internal Medicine, Semmelweis University, Budapest, Hungary; 4Novartis Pharma AG, Basel, Switzerland and 5Novartis Institutes for Biomedical Research, Cambridge, MA, USA Patients with severe hypertension (4180/110 mm Hg) LIS 3.4%). The most frequently reported AEs in both require large blood pressure (BP) reductions to reach groups were headache, nasopharyngitis and dizziness. recommended treatment goals (o140/90 mm Hg) and At end point, ALI showed similar mean reductions from usually require combination therapy to do so. This baseline to LIS in msDBP (ALI À18.5 mm Hg vs LIS 8-week, multicenter, randomized, double-blind, parallel- À20.1 mm Hg; mean treatment difference 1.7 mm Hg group study compared the tolerability and antihyperten- (95% confidence interval (CI) À1.0, 4.4)) and mean sitting sive efficacy of the novel direct renin inhibitor aliskiren systolic blood pressure (ALI À20.0 mm Hg vs LIS with the angiotensin converting enzyme inhibitor À22.3 mm Hg; mean treatment difference 2.8 mm Hg lisinopril in patients with severe hypertension (mean (95% CI À1.7, 7.4)). Responder rates (msDBPo90 mm Hg sitting diastolic blood pressure (msDBP)X105 mm Hg and/or reduction from baselineX10 mm Hg) were 81.5% and o120 mm Hg).
    [Show full text]
  • Angiotensin-Converting Enzyme (ACE) Inhibitors Single Entity Agents
    Therapeutic Class Overview Angiotensin-Converting Enzyme (ACE) Inhibitors Single Entity Agents Therapeutic Class Overview/Summary: The renin-angiotensin-aldosterone system (RAAS) is the most important component in the homeostatic regulation of blood pressure.1,2 Excessive activity of the RAAS may lead to hypertension and disorders of fluid and electrolyte imbalance.3 Renin catalyzes the conversion of angiotensinogen to angiotensin I. Angiotensin I is then cleaved to angiotensin II by angiotensin- converting enzyme (ACE). Angiotensin II may also be generated through other pathways (angiotensin I convertase).1 Angiotensin II can increase blood pressure by direct vasoconstriction and through actions on the brain and autonomic nervous system.1,3 In addition, angiotensin II stimulates aldosterone synthesis from the adrenal cortex, leading to sodium and water reabsorption. Angiotensin II exerts other detrimental cardiovascular effects including ventricular hypertrophy, remodeling and myocyte apoptosis.1,2 The ACE inhibitors block the conversion of angiotensin I to angiotensin II, and also inhibit the breakdown of bradykinin, a potent vasodilator.4 Evidence-based guidelines recognize the important role that ACE inhibitors play in the treatment of hypertension and other cardiovascular and renal diseases. With the exception of Epaned® (enalapril solution) and Qbrelis® (lisinopril solution), all of the ACE inhibitors are available generically. Table 1. Current Medications Available in Therapeutic Class5-19 Generic Food and Drug Administration
    [Show full text]
  • AVAPRO Rx Only (Irbesartan) Tablets
    NDA 20-757/S-038 Page 3 ® AVAPRO Rx only (irbesartan) Tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, AVAPRO should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality. DESCRIPTION ®* AVAPRO (irbesartan) is an angiotensin II receptor (AT1 subtype) antagonist. Irbesartan is a non-peptide compound, chemically described as a 2-butyl-3-[p-(o-1H-tetrazol-5- ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one. Its empirical formula is C25H28N6O, and the structural formula: Irbesartan is a white to off-white crystalline powder with a molecular weight of 428.5. It is a nonpolar compound with a partition coefficient (octanol/water) of 10.1 at pH of 7.4. Irbesartan is slightly soluble in alcohol and methylene chloride and practically insoluble in water. AVAPRO is available for oral administration in unscored tablets containing 75 mg, 150 mg, or 300 mg of irbesartan. Inactive ingredients include: lactose, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, poloxamer 188, silicon dioxide and magnesium stearate. CLINICAL PHARMACOLOGY Mechanism of Action Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system (RAS) and also stimulates aldosterone synthesis and secretion by adrenal NDA 20-757/S-038 Page 4 cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.
    [Show full text]
  • Summary of Product Characteristics
    Proposed var 24 psusa cilazapril SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT [Fosinopril sodium 10 mg, tablets] [Fosinopril sodium 20 mg, tablets] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 or 20 mg fosinopril sodium. Excipient with known effect: Each tablet fosinopril sodium 10 mg contains 87 mg of lactose, anhydrous. Each tablet fosinopril sodium 20 mg contains 174 mg of lactose, anhydrous. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. The 10 mg tablets are white and shaped like a capsule with indents. On one side they are engraved with the letters “APO” and on the other side with “FOS-10”. The 20 mg tablets are white and their shape is oval. On one side they are engraved with the letters “APO” and on the other side with “FOS-20”. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications - Treatment of hypertension. - Treatment of symptomatic heart failure. 4.2 Posology and method of administration Posology Fosinopril sodium should be administered orally in a single daily dose. As with all other medicinal products taken once daily, it should be taken at approximately the same time each day. The absorption of fosinopril sodium is not affected by food. The dose should be individualised according to patient profile and blood pressure response (see section 4.4). Hypertension: Fosinopril sodium may be used as a monotherapy or in combination with other classes of antihypertensive medicinal products (see section 4.3, 4.4, 4.5 and 5.1). Hypertensive patients not being treated with diuretics: Starting dose The initial recommended dose is 10 mg once a day.
    [Show full text]
  • Ace Inhibitors (Angiotensin-Converting Enzyme)
    Medication Instructions Ace Inhibitors (Angiotensin-Converting Enzyme) Generic Brand Benazepril Lotensin Captopril Capoten Enalapril Vasotec Fosinopril Monopril Lisinopril Prinivil, Zestril Do not Moexipril Univasc Quinapril Accupril stop taking Ramipril Altace this medicine Trandolapril Mavik About this Medicine unless told ACE inhibitors are used to treat both high blood pressure (hypertension) and heart failure (HF). They block an enzyme that causes blood vessels to constrict. This to do so allows the blood vessels to relax and dilate. Untreated, high blood pressure can damage to your heart, kidneys and may lead to stroke or heart failure. In HF, using by your an ACE inhibitor can: • Protect your heart from further injury doctor. • Improve your health • Reduce your symptoms • Can prevent heart failure. Generic forms of ACE Inhibitors (benazepril, captopril, enalapril, fosinopril, and lisinopril) may be purchased at a lower price. There are no “generics” for Accupril, Altace Mavik, and of Univasc. Thus their prices are higher. Ask your doctor if one of the generic ACE Inhibitors would work for you. How to Take Use this drug as directed by your doctor. It is best to take these drugs, especially captopril, on an empty stomach one hour before or two hours after meals (unless otherwise instructed by your doctor). Side Effects Along with needed effects, a drug may cause some unwanted effects. Many people will not have any side effects. Most of these side effects are mild and short-lived. Check with your doctor if any of the following side effects occur: • Fever and chills • Hoarseness • Swelling of face, mouth, hands or feet or any trouble in swallowing or breathing • Dizziness or lightheadedness (often a problem with the first dose) Report these side effects if they persist: • Cough – dry or continuing • Loss of taste, diarrhea, nausea, headache or unusual fatigue • Fast or irregular heartbeat, dizziness, lightheadedness • Skin rash Special Guidelines • Sodium in the diet may cause you to retain fluid and increase your blood pressure.
    [Show full text]
  • Download Leaflet View the Patient Leaflet in PDF Format
    Package leaflet: Information for the user Candesartan cilexetil 2 mg tablets Candesartan cilexetil 4 mg tablets Candesartan cilexetil 8 mg tablets Candesartan cilexetil 16 mg tablets Candesartan cilexetil 32 mg tablets candesartan cilexetil Read all of this leaflet carefully If you are going to have an operation, before you start taking this tell your doctor or dentist that you are medicine because it contains taking Candesartan cilexetil. This is important information for you. because Candesartan cilexetil, when - Keep this leaflet. You may need combined with some anaesthetics, to read it again. may cause an excessive drop in - If you have any further questions, blood pressure. ask your doctor or pharmacist. - This medicine has been Children and adolescents prescribed for you only. Do not Candesartan Cilexetil has been pass it on to others. It may harm studied in children. For more them, even if their signs of illness information, talk to your doctor. are the same as yours. Candesartan Cilexetil must not be - If you get any side effects, talk to given to children under 1 year of your doctor or pharmacist. This age due to the potential risk to the includes any possible side effects developing kidneys. not listed in this leaflet. See Other medicines and Candesartan section 4. cilexetil What is in this leaflet Tell your doctor or pharmacist if you 1. What Candesartan cilexetil is and are taking, have recently taken or what it is used for might take any other medicines. 2. What you need to know before you take Candesartan cilexetil Candesartan cilexetil can affect the 3.
    [Show full text]
  • BENICAR HCT Tablets
    ® BENICAR HCT Tablets (OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE) WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Benicar HCT as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity DESCRIPTION BENICAR HCT® (olmesartan medoxomil-hydrochlorothiazide) is a combination of an angiotensin II receptor antagonist (AT1 subtype), olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide (HCTZ). Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan medoxomil is 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2­ propyl-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3­ carbonate. Its empirical formula is C29H30N6O6 and its structural formula is: Olmesartan medoxomil is a white to light yellowish-white powder or crystalline powder with a molecular weight of 558.6. It is practically insoluble in water and sparingly soluble in methanol. Hydrochlorothiazide is 6-chloro-3,4-dihydro-2H-1,2,4-benzo-thiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C7H8ClN3O4S2 and its structural formula is: 1 Reference ID: 3227549 Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.7. Hydrochlorothiazide is slightly soluble in water but freely soluble in sodium hydroxide solution. BENICAR HCT® is available for oral administration in tablets containing 20 mg or 40 mg of olmesartan medoxomil combined with 12.5 mg of hydrochlorothiazide, or 40 mg of olmesartan medoxomil combined with 25 mg of hydrochlorothiazide. Inactive ingredients include: hydroxypropylcellulose, hypromellose, lactose, low-substituted hydroxypropylcellulose, magnesium stearate, microcrystalline cellulose, red iron oxide, talc, titanium dioxide and yellow iron oxide.
    [Show full text]
  • "Coaprovel, INN-Irbesartan+Hydrochlorothiazide"
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT CoAprovel 150 mg/12.5 mg tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide. Excipient with known effect: Each tablet contains 26.65 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1). 4.2 Posology and method of administration Posology CoAprovel can be taken once daily, with or without food. Dose titration with the individual components (i.e. irbesartan and hydrochlorothiazide) may be recommended. When clinically appropriate direct change from monotherapy to the fixed combinations may be considered: . CoAprovel 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone; . CoAprovel 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by CoAprovel 150 mg/12.5 mg. CoAprovel 300 mg/25 mg may be administered in patients insufficiently controlled by CoAprovel 300 mg/12.5 mg. Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended. When necessary, CoAprovel may be administered with another antihypertensive medicinal product (see sections 4.3, 4.4, 4.5 and 5.1).
    [Show full text]